We survey some interesting features of gene expression in non-endocrine pancreatic cancer, the response to some less widely known agents as they impact on pancreatic cell proliferation and programmed death, and several developing approaches to therapy. The proliferative and cellular suicide responses of Panc-1 cells to the free radical spin trap, NTBN, and to the 5-lipoxygenease inhibitor, MK 886, the latter assessed with CLONTECH Atlas Human cDNA Array 1, are reviewed. Difficulties in identifying those factors whose suppression or augmentation could result in inhibition of malignantly transformed cell properties are considered.
Cancer Facts and Figures, 2000. Atlanta: American Cancer Society, 2000.
2.
FisherDE. Apoptosis in cancer therapy: Crossing the threshold. Cell78: 539542, 1996.
3.
GjertsenBT, CressyLI, RuchaudS, HougeG, LanotteM, DoskelandSO. Multiple apoptotic death types triggered through activation of separate pathways by cAMP and inhibitors of protein phosphatases in one (IPC leukemia) cell line. J Cell Sci107: 33633377, 1994.
LohrJ-M, ColcherD, HollingsworthMA, LiebeS. Cell and molecular biology of pancreatic carcinoma. NY Acad Sci880: 1378, 1999.
7.
Van IngenM, van Leeuwen-StokAE, Ruiz van HapernVWT. Biliopancreatic malignancy: From gene to cure. Ann Oncol10(Suppl):1311, 1999.
8.
HrubanRH, PetersenGM, HaPK, KernSE. Genetics of pancreatic cancer: From genes to families. Surg Oncol Clin N A7: 123, 1998.
9.
HrubanRH, PetersenGM, CogginsM. Familial pancreatic cancers. Ann Oncol10: 6973, 1999.
10.
HoweJR, ConlonKC. The molecular genetics of pancreatic cancer. Surg Oncol6: 118, 1997.
11.
CoppolaD. Molelcular prognostic markers in pancreatic cancer. Cancer Cont7: 421427, 2000.
12.
SolciaE, CapellaC, KloppelG. Atlas of Tumor Pathology: Tumors of the Pancreas. Third Series, Fascicle 29. Washington, DC: Armed Forces Institute of Pathology, 1997.
13.
PourPM, SchmiedB. The link between exocrine pancreatic cancer and the endocrine pancreas. Int J Pancreat25: 7787, 1999.
14.
HahnSA, SeymourAB, HoqueATM, SchutteM, de CostaLT, RedstoneMS, CalrosC, WeinsteinCL, FiasherA, YeoCJ, HrubanRH, KernSE. Allelotype of pancreatic adenocarcinomas using xenograft enrichment. Cancer Res55: 46704675, 1995.
15.
Solinas-ToldoS, WallrappC, Muller-PillaschF, BentyM, GressT, LichterP. Mapping of chromosomal imbalances in pancreatic carcinoma by comparative genome hybridization. Cancer Res56: 38033807, 1996.
16.
GriffinCA, HrubanRH, MorsbergerLA, EllinghamT, LongPP, JaffeeEM, HaudaKM, BohlanderSK, JeoCJ. Consistent chromosome abnormalities in adenocarcinoma of the pancreas. Cancer Res55: 23942399, 1995.
17.
FukushigeS, FurukawaT, SatohK, SunamuraM, KohariM, KoizumiM, HoriiA. Loss of chromosonme 18q is an early event in pancreatic ductal tumorigenesis. Cancer Res58: 42224226, 1998.
18.
FrazierML. Gene expression in pancreatic adenocarcinoma. NY Acad Sci880: 14, 1999.
19.
SuGH, HrubanRH, BansalPK, BovaGS, TangDJ, ShekherMC, WestermanAW, EntiusMM, CogginsM, YeoCJ, KernSB. Germ-line and somatic mutations of the STK11/LKB 1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol154: 18351840, 1999.
20.
LalG, LiuG, SchmockerB, KaurahP, OzcelikH, NarodSA, RedstoneM, GallingerS. Inherited predisposition to pancreatic adenocarcinoma: Role of family history and germ-line p16, BRCA1 and BRCA2 mutations. Cancer Res60: 409416, 2000.
21.
OzcelikH, ShmockerB, Di NicolaN, ShiX-H, LangerB, MooreM, TaylorBR, NarodSA, DarlingtonG, AndrulisIL, GallingerS, RedstonM. Germline BRCA2 6174delT mutations in Ashkenazhi Jewish pancreatic cancer patients. Nat Genet16: 1718, 1997.
22.
LaiG, LiuL, HoggD, Lassam RedstoneMS, GallingerS. Patients with both pancreatic adenocarcinoma and melanoma may harbor germline CDKN2A mutations. Genes Chromosomes Cancer27: 358361, 2000.
23.
VelculescuVE, ZhangL, VogelsteinB, KinzlerKW. Serial analysis of gene expression. Science270: 484487, 1995.
24.
ZhouW, SokollU, BruzekDJ, ZhangL, VelculescuVE, GoldinSB, HrubamRH, KernSE, HamiltonSR, ChanDW. Identifying markers for pancreatic cancer by gene exression analysis. Cancer Epidemiol Biomark Prevent7: 109112, 1998.
25.
GressTM, Muller-PulischF, GengM. A pancreatic-specific expression profile. Oncogene13: 18191830, 1996.
26.
AndersonKM, SeedT, MengJ, OuD, AlrefaiWA, HarrisJE. Five-lipoxygenase inhibitors reduce Panc-1 survival: The mode of cell death and synergism of MK 886 with gamma linolenic acid. Anticancer Res18: 791800, 1998.
27.
AndersonKM, AlrefaiWA, BonomiP, DudejaP, OuD, AndersonC, HarrisJE. Altered oncogene, tumor suppressor and cell-cycle gene expression in Panc-1 cells cultured with the pleiotrophic 5-lipoxygenase inhibitor, MK 886, assessed with a gene chip. Anticancer Res19: 38733888, 1999.
28.
AlrefaiW, AndersonKM, BonomiP, HarrisJE. MK 886 functions as a radiomimetic agent: Genomic responses related to oxidative stress, the cell cycle, proliferation and programmed cell death in Panc-1 cells. Sixth Internationl Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases, Boston, MA, 1999. Raven Press.
29.
AndersonKM, AlrefaiWA, AndersonCA, BonomiP, HarrisJE. Widespread countervailing genomic responses induced by chemotherapy or radiation as a cause of therapeutic failure. Med Hypo54: 10001002, 2000.
30.
AlmogueraC, ShibataD, ForresterK, MartinJ, ArnheimN, PeruchoM. Most human carcinomas of the exocrine pancreas contain mutant c-k-ras genes. Cell53: 549554, 1998.
31.
BergerDH, JardinesLA, ChangH, RuggeriB. Activation of Raf-1 in human pancreatic adenocarcinoma. J Surg Res69: 199204, 1997.
OhnamiS, MatsusmotoN, NakanoM, AokiK, NagasakiK, SugimuraT, TeradaM, YoshidaT. Identification of genes showing differential expression in antisense K-ras transduced pancreatic cancer cells with suppressed tumorigenicity. Cancer Res59: 55655571, 1999.
34.
YamanakaY, FreissH, KobrinMS, BuchlerM, KunzJ, BegerHG, KorcM. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Human Pathol24: 11271134, 1993.
35.
SafranH. Her-2/neu overexpression in pancreatic adenocarcinoma. (abstract)Proc ASCO-American Association of Clinical Oncology19: 1251, 2000.
36.
SlebosRJC, CehaHM, KernSE. Molecular genetics of pancreatic cancer. In: SakarFH, DuganMC, Eds. Pancreatic Cancer: Advances in Molecular Pathology, Diagnosis and Clinical Management. Natuick, MA: Bio-Techniques Books, pp 6582, 1998.
37.
RommelC, ClarkeBA, ZimmermannS. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science286: 17381741, 1999.
38.
ZimmermannS, MoellingK. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science286: 17411744, 1999.
39.
WallrappC, Muller-PillaschF, Solinas-ToldoS, LichterP, FreissH, BuchlerM, FinkT, AdlerG, GressTM. Characterization of a high copy number amplification at 6q24 in pancreatic cancer identifies c-myb as a candidate oncogene. Cancer Res57: 31353139, 1997.
40.
CaldasC, HahnSA, da CostaLT, RedstoneMS, SegutteM, SeymourAB, WeinsteinCL, HrubanRH, YeoCJ, KernSE. Frequent somatic mutations and homozygous deletions of the p16 (MST1) gene in pancreatic adenocarcinoma. Nat Genet8: 2731, 1994.
41.
SchutteM, HrubanRH, GeradtsJ, MaynardR, HilgdersW, RabindranSR, MoskalukCA, HahnSA, Schwarte-WaldhoffI, SchmiegelW, BaylinSB, KernSE, HermanJG. Abrogation of the Rb/p16 tumor suppressive pathway in virtually all pancreatic adenocarcinoma. Cancer Res57: 31263130, 1997.
42.
HuYT, WatanabeH, OhtsuboK, YamaguchiY, HaA, OkaiT, SawabuN. Frequent loss of p16 expression and its correlation with clinicopathological parameters in pancreatic cancer. Clin Cancer Res3: 14731477, 1997.
43.
RedstonMS, CaldasC, SeymourAB, HrubanRH, de CostaL, YeoCJ, KernSE. P53 mutations in pancreatic carcinoma and evidence of common involvement of homopolymer tracts in DNA microdeletions. Cancer Res54: 30253033, 1994.
44.
SuwaH, OhshioG, OkadaN, WangZ, FukumotoM, ImamuraT, ImanuraM. Clinical significance of serum p53 antigen in patients with pancreatic cancer. Gut40: 647653, 1997.
45.
HahnSA, SchutteM, ShamsulA, HoqueATM, MoskalukCA, da CostaLT, RozenblumE, WeinsteinCL, FischerA, YeoCJ, HrubanRH, KernSE. DPC4, a candidate tumor supressor gene at human chromosome 18q21.1. Science271: 350353, 1996.
46.
ChiaoPL, HuntKK, GrauAM. Tumor suppressor gene SMAD4/DPC4, its downstream target genes, and regulation of cell cycle. Ann NY Acad Sci880: 3136, 1999.
47.
WilentzRE, Iacobuzio-DonahueCA, ArganiP, McCarthyDM, ParsonsJL, YeoCJ, KernSE, HrubanRH. Loss of expression of DPC4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res60: 20022006, 2000.
48.
RozenblumE, SchutteM, CogginsM, HahnSA, PanzerS, ZahuraklM, GoodmanSN, SohnTA, HrubanRH, YeoCJ, KernSE. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res57: 17311734, 1997.
49.
GogginsM, SchutteM, LuJ, MoskalukA, WeinsteinCL, PetersonGM, YeoCJ, JacksonCE, LynchHT, HrubanRH, KornSE. Germ-line BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res56: 53605364, 1996.
50.
BartonCM, McKieAB, HoggA. Abnormalities of the RBI and DCC tumor suppressor gene: Uncommon in human pancreatic carcinoma. Mol Carcin13: 6169, 1995.
51.
KiehneK, HerzogKH, FolschUR. C-met expression in pancreatic cancer and effects of hepatocyte growth factor on pancreatic cancer cell growth. Pancreas15: 3540, 1997.
52.
SorioC, BaronA, OrlandiniS, ZamboniG, PederzoliP, HuebnerK, ScarpaA. The FHIT gene is expressed in pancreatic ductal cells and is altered in pancreatic cancers. Cancer Res59: 13081314, 1999.
53.
SuGH, HilgersW, ShekherMC, TangDJ, YeoCJ, HrubanRH, KernSE. Alterations in pancreatic, biliary and breast carcinomas support MKK4 as a generally targeted tumor suppressor gene. Cancer Res58: 23392342, 1998.
54.
MoskalinkCA, HrubanRH, KernSE. p16 and k-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res57: 21402143, 1997.
55.
LuC-D, MoritaS, IshibashiT, HaraH, IsozakiH, TamigawaN. Loss of p27kipi expression independently predicts poor prognosis for patients with resectable pancreatic adenocarcinoma. Cancer85: 12501260, 1999.
56.
DerghamST, DuganMC, JoshiUS, ChenYC, DuW, SmithDW, ArlauskasP, CrissmanJD, VaitkeviciusVK, SarkarFH. The clinical significance of p21waf/cip-1 and p53 expression in pancreatic adenocarcinoma. Cancer80: 372381, 1997.
57.
GansaugeS, GansaugeF, RamadaniM, StubbeH, RauB, HaradaN, BegerHG. Overexpression of cyclin D1 in human pancreatic crcinomas is associated with poor prognosis. Cancer Res57: 16341637, 1997.
58.
KornmannM, DanenbergKD, ArberN, BergerHG, DannenbergPV, KorcM. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res59: 35053511, 1999.
59.
GreweM, GansaugeF, SchmidRM, AdlerG, SeufferleinT. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70S6K pathway in human pancreatic cancer cells. Cancer Res59: 35803587, 1999.
60.
Flossmann-KastBBM, JehlePM, HoeflichA, AdlerG, LutzMP. Src stimulated insulin-like growth factor I (IGF-I)-dependent cell proliferation by increasing IGF-I receptor number in human pancreatic carcinoma cells. Cancer Res58: 35513554, 1998.
61.
UkeiT, ToyotaM, SohnT, YeoCJ, IssaJP-J, HrubanRH, CogginsM. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res60: 18351839, 2000.
62.
RuggeM, SonegoF, SessaF, LeandroG, CapellaC, SpertiC, PasqualiC, Di MarioF, PedrazzoliS, NinfoV. Nuclear DNA content and pathology in radically treated pancreatic carcinoma: The prognostic significance of DNA ploidy, histology and nuclear grade. Cancer77: 459466, 1996.
63.
CogginsM, OfferhausGJA, HilgersW, GriffinCA, ShekherM, TangD, SohnTA, YeoCJ, KernSE, HrubanRH. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Am J Pathol152: 15011507, 1998.
64.
HanH-J, YanagisawaA, KatoY, ParkJ-G, NakamuesY. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer. Cancer Res53: 50875089, 1993.
65.
ZhongQ, ChenC-F, LiS, ChenY, WangC-C, XiaoJ, ChenP-L, SharpZD, LeeW-H. Association of BRCA 1 with the hRAD50 hMre11-p95 complex and the DNA damage response. Science285: 747750, 1999.
66.
FiroziPF, AbbruzzeseJL, EvansDB, FeissH, LiD. DNA adducts, oxidative DNA damage and genetic polymorphisms in pancreatic cancer. (abstract)Proc Am Assoc Cancer Res41: 3725, 2000.
67.
YamasawaK, NioY, ItakuraM, TamuraK. Expression of growth-arrest and DNA damage-inducible (GADD) 45 protein in resectable invasive ductal carcinoma (IDC) of the pancreas. (abstract)Proc Am Assoc Cancer Res41: 3355, 2000.
68.
FreissH, GuoX-Z, NanB-C, KleeffO, BuchlerMW. Growth factors and cytokines in pancreatic carcinogenesis. Ann NY Acad Sci880: 110121, 1999.
69.
FreissH, BuchlerMW, KorcM. Growth factors and growth factor receptors in pancreatic cancer. In: NeoptolemosJP, LemoineNR, Eds. Pancreatic Cancer: Molecular and Clinical Advances. Oxford: Blackwell, pp 5160, 1996.
70.
HarbisonMT, BurnsCJ, DavisDW, TsanR, PorteraG, McConkeyDJ, RadinskyR. Regression of human pancreatic carcinoma and inhibition of metastases by blockade of EGF-R signal transduction is enhanced in combination with gemcitabine. (abstract)Clin Cancer Res5: 31, 1999.
71.
SchmielauJ, KalthoffH, RoederC, SchmiegelW. Cytokines and the biology of pancreatic cancer. In: NeoptolemosJP, LemoineNR, Eds. Pancreatic Cancer: Molecular and Clinical Advances. Oxford: Blackwell, pp 3650, 1996.
72.
TachibanaI, ImotoM, AdjeiPN, GoreGJ, SubramaniamM, SpelsbergTC, UrrutiaR. Overexpression of the TGF-β-regulated zinc finger encoding gene, TIEG induces apoptosis in pancreatic epithelial cells. J Clin Invest99: 23652374, 1997.
RealFX. The cell biology of pancreatic cancer: an overview. In: NeoptolemosJP, LemoineNR, Eds. Pancreatic Cancer: Molecular and Clinical Advances. Oxford: Blackwell, pp 117, 1996.
76.
BharatJ, PuriRK. Identification and characterization of IL-13 and IL-4 receptor complex in pancreatic carcinoma cells. (abstract)Clin Cancer Res5: 375, 1999.
77.
SchlosserS, GansaugeF, SchnelldorferT, RamadianM, SchwarzA, BergerHG, GansaugeS. Inhibition of epidermal growth factor-induced interleukin-1β-converting enzyme expression reduces proliferation in the pancreatic carcinoma cell line AsPC-1. Cancer Res59: 15511554, 1999.
78.
BergmannU, FunatomiH, YokoyamaM. Insulin-like growth factor 1 overexpression in human pancreatic cancer: Evidence for autocrine and paracrine roles. Cancer Res55: 20072011, 1995.
79.
KornmannM, MuruyamaH, BergmannU. Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer. Cancer Res58: 42504254, 1998.
80.
YamanakaY, FriessH, BuchlerM, BergerHG, UchidaE, OndaM, KobrinMS, KorcM. Overexpression of acidic and basic fibroblast growth factors in pancreatic cancer correlate with advanced tumor state. Cancer Res53: 52895296, 1993.
81.
WeinbergDS, RuggeriB, BarberMT, BiswasS, MiknyokiS, WaldmanSA. Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma. J Clin Invest100: 597603, 1997.
82.
GansaugeS, NusslerAK, BergerHG, GansaugeF. Nitric oxide-induced apoptosis in human pancreatic carcinoma cell lines is associated with a G1-arrrest and an increase of the cyclin-dependent kinase inhibitor p21WAF/CIP1. Cell Growth Diff9: 611617, 1998.
83.
TangDG, ChenYQ, HonnKV. Arachidonate lipoxygenases as essential regulators of cell survival and apoptosis. Proc Natl Acad Sci U S A93: 52415246, 1996.
84.
DingX, AdrianTE. 12-Lipoxygenase activity stimulated pancreatic cancer cell proliferation through activation of the ERK MAP kinase pathway. (abstract)Proc Am Assoc Cancer Res41: 1306, 2000.
MiyamotoY, HosotaniR, WadaM. Immunohistochemical analysis of Bcl-2, Bax, and Mcl-1 expression in pancreatic cancer. Oncology56: 7382, 1999.
87.
UngerfrorenH, VossM, JansenM, RoederC, Henne-BrunsD, KremerR, KalthoffH. Human pancreatic adenocarcinoma express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis. Cancer Res68: 17411749, 1998.
88.
BoldRJ, ChandraJ, McConkeyDJ. Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by BCL-2 content, Ann Surg Oncol6: 279285, 1999.
89.
UngeforenH, HinzS, BoenickeL, KalthoffH. BCL-XL protects human pancreatic carcinoma cells against trail-induced apoptosis. (abstract)Proc Am Assoc Cancer Res41: 3353a, 2000.
90.
KleeffJ, KornmannM, SawhneyH, KorcM. Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. Int J Cancer86: 399407, 2000.
91.
AndersonKM, SeedT, AlrefaiW, OuD, HarrisJE. NTBN, a free radical spins trap, induces programmed cell death in human pancreatic cancer (PANC-1) cells. Anticancer Res18: 32133222, 1998.
92.
AndersonKM, AalrefaiWA, OuD, HarrisJE. BCL-2 is expressed in U937 but absent in PC-3 and Panc-1 cells. (abstract)Proc Am Assoc Cancer Res40: 1440, 1999.
93.
WangW, ElshihabiS, Von HoffDD, WalersSJ, MacdonaldJr.. MGI 114 induces a multiple caspase activation cascade in human pancreatic cancer. (abstract)Clin Cancer Res5: 266a, 1999.
94.
HarbisonMT, BrunsCJ, BoldRJ, ElliotPJ, AdamsJ, AbbruzzeseJL, McConkeyDJ. Proteasome inhibitor PS-341 effective as an anti-angiogenetic agent in the treatment of human pancreatic carcinoma via the inhibition of NF-kB and subsequent inhibition of vascular endothelial growth factor production. (abstract)Proc Am Assoc Cancer Res41: 53, 2000.
95.
BegAA, BaltimoreD. An essential role for NH-kB in preventing TNF-induced cell death. Science274: 782784, 1999.
96.
WangC-Y, MayoMW, BaldwinAS. TNF and cancer therapy- induced apoptosis: Potentiation by inhibition of NF-kB. Science274: 784787, 1999.
97.
van AntwerpDJ, MartinSJ, KafriT, GreenDR, VermaIM. Suppression of TNF-α-induced apoptosis by NF-kB. Science274: 787789, 1999.
98.
ItakuraM, NioY, IguchiC, YamasawaK, HashimotoK, OhmoriH, YanoS, SumaS, TamuroK. A possible mechanism for escape from FAS-mediated apoptosis in pancreatic invasive ductal carxcinoma (ICD). (abstract)Proc Am Assoc Cancer Res41: 3356, 2000.
99.
NairPN, FreemanJW. Cross-talk between IGF-1R and EGFR signaling in maintaining growth fraction independence and resistance to apoptosis in the pancreatic cancer cell line MIA PACA-2. (abstract)Proc Am Assoc Cancer Res41: 3347, 2000.
100.
NgSSW, TsaoMS, ChowS, HedleyDW. Inhibition of phosphatidylinositol 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res60: 54515455, 2000.
101.
RosenKV, RakJ, LeungT, KerbelRS, FilmusJ. BCL-2 family members as mediators of RAS-induced transformation. (abstract)Proc Am Assoc Cancer Res41: 2803a, 2000.
102.
McDadeTP, PeruginiRA, VittimbergaFJ, CarriganRC, CalleryMP. Salicylates inhibit NF-kB activation and enhance TNF-alpha-induced apoptosis in human pancreatic cncer cells. J Surg Res83: 5661, 1999.
103.
HoughtonJA. Apoptosis and drug response. Curr Opin Oncol11: 475481, 1999.
104.
El-DeiryWS. Role of oncogenes in resistence and killing by cancer therapeutic agents. Curr Opin Oncol9: 7987, 1997.
105.
OuD, AndersonKM, LeslieW, BonomiP, HarrisJE. Does maximizing programmed cell death necessarily yield an optimum clinical advantage?Med Hypo52: 235238, 1999.
106.
KiarisH, SchallyAV. Apoptosis versus necrosis: Which should be the aim of cancer therapy?Proc Soc Exp Biol Med221: 8788, 1999.
107.
BurnsCP, WagnerBA. The effect of exogenous lipids on cancer and cancer chemotherapy. Drug Safety8: 5768, 1993.
108.
HorrobinDF. Medical roles of metabolites of precursor EFA. Inform6: 428435, 1995.
109.
LaiPBS, RossT, FearonKCH, AndersonJD, CarterDC. Cell cycle arrest and induction of apoptosis in pancreatic cancer cells exposed to eicosapentaenoic acid in vitro. Br J Cancer74: 13751383, 1996.
110.
AndersonKM, OndreyF, HarrisJE. ETYA, a pleiotropic membraneactive arachidonic acid analogue affects multiple signal transduction pathways in cultured transformed mammalian cells. Clin Biochem26: 19, 1992.
111.
SumiS, BeauchampRD, TownsendCM, UchidaT, MurakamiM, RajaramanS, IshizukaJ, ThompsonJC. Inhibition of pancreatic carcinoma cell growth by lovastatin. Gastroenterolgy103: 982989, 1992.
112.
MorrisTJ, PalmSL, FurchtLL, BuchwaldH. Effect of lovastatin alone and as an adjuvant chemotherapeutic agent on hepatoma tissue culture-4 cell growth. Ann Surg Oncol2: 266274, 1995.
113.
BarthelmanM, ChenW, GenslerHL, HuangC, DongZ, BowdenT. Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation. Cancer Res58: 716, 1998.
114.
StarkMJ, BurkeYD, McKinzieJH, AyoubiAS, CrowellPL. Chemotherapy of pancreatic cancer with the monoterpene perillyl alcohol. Cancer Lett96: 1521, 1995.
ShackS, ChenL, MillerAC, DanesiR, SamidD. Increased susceptibility of ras-transformed cells to phenylacetate is associated with inhibition of p21 ras isosprenylation and phenotypic reversion. Int J Cancer63: 124129, 1995.
117.
WickM, MangoldG, DexterD, PerkinsW, EckhardtG, Von HoffD. Combination drug study with sodium phenylacetate and gemcitabine against the MiaPaCa human pancreatic cancer xenograft. (abstract)Proc Am Assoc Cancer Res38: 586, 1997
118.
ThibaultA, SamidD, CooperMK, FiggWD, TompkinsAC, PatronasN, HeadierDJ, KohlerDR, VenzonDJ, MyersCE. Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer75: 29322938, 1995.
WrightJ, BlatnerGL, ChesonBD. Clinical trials with the farnesyl transferase inhibitor R115777. Oncology13: 15271528, 1999.
121.
RotherbergML, BerlinJD. Noncytotoxic approaches to the treatment of advanced pancreatic cancer.(abstract)Proc Am Soc Cancer Oncol19: 724728, 2000.
122.
KernSE. Advances from genetic clues in pancreatic cancer. Curr Opin Oncol19: 7480, 1998.
123.
OkamiJ, YamamotoH, FujiwaraY, TsujieM, KondoM, NouraS, OshimaS, NaganoH, DonoK, UmeshitaK, IshikawaO, SakonM, MatsuuraN, NakamoriS, MondenM. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res5: 20182924, 1999.
124.
MolinaMA, Sitja-ArnauM, LemoineMG, FrazierML, SinicropeFA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res59: 43564362, 1999.
125.
MolinaMA, Sitja-ArnauM, LemoineMG, FrazierML, SinicropeFA. Cyclooxygenase inhibitors exert antiproliferative effects against pancreatic adenocarcioma cell lines that are independent of the level of COX-2 expression. (abstract)Clin Cancer Res5: 686, 1999.
126.
PiazzaGA, Kulchak RahmAL, KrutzschM, SperlG, Shjipp ParankaN, GrossPH, BrendelK, BurtRW, AlbertsDA, PamukcuR, AhnenDJ. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res55: 31103116, 1995.
127.
JonesL, GhanehP, HumphreysM, NeoptolemosJP. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann NY Acad Sci880: 288307, 1999.
128.
BremS. Angiogenesis and cancer control: From concept to therapeutic trial. Cancer Control6: 436458, 1999.
129.
LushRM, RudekMA, FiggWD. Review of three new agents that target angiogenesis matrix metalloproteinases and cyclin-dependent kinases. Cancer Control6: 459463, 1999.
130.
RasmussenHS, McCannPP. Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat. Pharmacol Ther75: 6975, 1997.
131.
CarmichaelJ, LedermannJA, WollRI, GullifordT, RussellRC. A phase 1b study of concurrent administration of marimastat and gemcitibine in non-resectable pancreatic cancer. (abstract)Am Soc Cancer Oncol Proc17: 888, 1998.
132.
O'riellyS, ManiS, RatainMJ, BrownKE, VogelzangNJ, KennedyMK, DonehawerRC, RuggT. Schedules of 5-FU and the matrix metalloproteinase inhibitor marimistat, a phase I study. (abstract)Am Soc Cancer Oncol Proc17: 839, 1998.
133.
RosemurgyA, HarrisJ, LanglebenA, CasperE, GoodeS, RasmussenH. Marimastat in patients with advanced pancreatic cancer: A dose-finding study. Am J Clin Oncol22: 247252, 1999.
134.
RieckenEO, RosewiczS. Retinoids in pancreatic cancer. Ann Oncol10(Suppl 4):197200, 1999.
135.
BrembeckFH, SchoppmeyerK, LeupoldU, GornistuC, KeimV, MossnerJ, RieckenE-O, RosewiczS. A phase II pilot trial of 13-cis retinoic acid and interferon-α in patients with advanced pancreatic carcinoma. Cancer83: 23172323, 1998.
136.
GaslL, HermennT, StreuerM, ZmijaJ, GunsiliusE, UngerC, KraftA. Angiogenesis as a target for tumor treatment. Oncology54: 177184, 1997.
137.
von HinsberghVWM, CollenA, KoolwijkP. Angiogenesis and antiangiogenesis: Perspectives for treatment of solid tumors. Ann Oncol10: 6063, 1999.
138.
ShimoyamaS, GansaugeF, GansaugeS, NegriO, OoharoT, BergerHG. Increased angiogenin expression in pancreatic cancer is related to cancer aggressiveness. Cancer Res56: 27032706, 1996.
139.
HarbisonMT, BrunsCJ, BoldRJ, ElliotJP, AdamsJ, AbbruzzeseJ, McConkeyDJ. Proteasome inhibitor PS-341 effective as an anti-angiogenic agent in the treatment of human pancreatic cancer via the inhibition of NF-kB and subsequent inhibition of vascular growth factor production. (abstract)Clin Cancer Res5: 414, 1999.
140.
WangB, ShiQ, LeX, HuangS, AbbruzzeseJL, XieK. Constitutive expression of vascular endothelial growth factor correlates with growth and metastases of human pancreatic adenocarcinoma. (abstract)Clin Cancer Res5: 412, 1999.
141.
TaniguchiT, KakkarAK, TuddenhamEGD, WilliamsonRCN, LemoineNR. Enhanced expression of urokinase receptor induced through the tissue factor-Factor VIIa pathway in human pancreatic cancer. Cancer Res58: 45584561, 1998.
142.
GansaugeF, GansaugeS, RauB, ScheiblichA, PochB, SchoenbergMH, BergerHG. Low serum levels of soluble CD44 variant 6 was significantly associated with poor prognosis in patients with pancreatic cancer. Cancer80: 17331739, 1997.
143.
SlaterAFG, NobelCSI, MaellaroE, BustamanteJ, KimlandM, OrreniusS. Nitrone spin traps and a nitroxide antioxidant inhibit a common pathway of thymocyte apoptosis. Biochem J306: 771778, 1995.
144.
AndersonKM, OuD, WuY, JajehA, HarrisJE. Induction of type I programmed cell death in U937 cells by the antioxidant butylated hydroxy-toluene or the free radical spin trap, NTBN. Leuk Res23: 665673, 1999.
145.
PurpuraP, WestmanL, WillP, EidelmanA, KaganVE, OsipovAN, SchorNF. Adjuvant treatment of murine neuroblastoma with 6-hydroxy dopamine and tempol. Cancer Res56: 23362342, 1996.
DrukerBJ, KentarjianH, SawyersCJ, RestaD, ReeseSF, FordJ, TalpazM. Activity of an ABL-specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemia, including CML in blast crisis. (abstract)Blood94S: 3082, 1999.
153.
MiknyoczkiSJ, DionneCA, Klein-SzantoAJP, RuggerBA. The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits anti-tumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness. NY Acad Sci880: 252262, 1999.
154.
LiuJ-P. Studies of the molecular mechanisms in the regulation of telomerase activity. FASEB J13: 20912104, 1999.
155.
KimNW, PiatyszekMA, ProwseKR. Specific association of human telomerase activity with immortal cells and cancer. Science266: 20112015, 1995.
156.
JoshiSS, PalenBN, MataJE, IversenPL. Growth inhibiting effects of telomere mimic-oligonucleotides on human leukemia/lymphoma cells. (abstract)Proc Am Assoc Cancer Res55: 2449, 1995.
157.
SueharaN, MizumotoK, MutaT, TominagaY, ShimuraH, KitajimaS, HamasakiN, TsungyoshiM, TanakaM. Telomerase elevation in pancreatic ductal carcinoma compared to nonmalignant pathological states. Clin Cancer Res3: 993998, 1997.
158.
IwaoT, HiyzmaE, YokoyamaT, TouchidaA, MurakamiY, ShimamutoF, ShayJW, KajiyamaG. Telomerase activity for the preoperative diagnosis of pancreatic cancer. J Natl Cancer Inst89: 16211623, 1997.
159.
RhaSY, SunD, DavidsonKK, IzbickaE, von HoffDD. Inhibitory effect of gemcitabine on telomerase in a human pancreatic cancer. (abstract)Clin Cancer Res5: 497, 1999.
160.
HochesterHS. 9-Nitro-camptothecin therpy of pancreatic cancer. (abstract)Cancer Invest18: 20, 2000.
161.
UsluR, SezginC, KarabulutB, SanliUA, TobuM, SaydamG. Arsenic trioxide-mediated cytotoxicity in prostate and ovarian carcinoma lines. (abstract)Clin Cancer Res5: 271, 1999.
162.
MaehamaT, DixonJE. The tumor suppressor, PTEN/MMAC-1, dephosphorylates the lipid second messenger, phosphatidyl inositol, 3,4,5-trisphosphate. J Biol Chem273: 1337513378, 1998.
163.
RamehLE, CantleyLC. The role of phosphoinositide 3-kinase lipid products in cell function. J Biol Chem274: 83478350, 1999.
164.
SmithJP, VerderameMF, ZagonIS. Antisense oligonucleotides to gastrin inhibit growth of human pancreatic cancer. Cancer Lett135: 107112, 1999.
165.
FunatomiH, ItakuraJ, IshawataT, PastanI, ThompsonSA, JohnsonGR, KorcM. Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitized the cells to EGF receptor-targeted therapy. Int J Cancer72: 512517, 1997.
166.
RosewiczS, BrembeckF, KaiserA, MarschallZV, RiechenE-O. Differential growth regulation by all trans retinoic acid is determined by protein kinase C in human pancreatic carcinoma cells. Endocrinology137: 33403347, 1996.
167.
KazunoriA, ShumpeiO, MasaruN, MasaakiT, TeruhikoY. Identification of genes showing altered expression in antisense K-ras-transduced pancreatic cancer cells with suppressed tumorigenicity. (abstract)Clin Cancer Res5: 592, 1999.
168.
BrayD. Intracellular signaling as a parallel distributed process. J Theor Biol143: 215231, 1990.
169.
DenningPJ. Neural networks. Am Sci80: 426429, 1992.
ShanksN, JoplinKH. Redundant complexity: A critical analysis of intelligent design in biochemistry. Phil Sci66: 268282, 1999.
172.
KeysDN, LewisDL, SelequeJE, PearsonBJ, GoodrichLV, JohnsonRL, GatesJ, ScottMP, CarrollSB. Recruitment of a hedgehog regulatory circuit in butterfly eyespot evolution. Science283: 523537, 1999.
173.
LemoineNK. Strategies for genetic intervention in pancreatic cancer. In: NeoptolemosJP, LemoineNR, Eds. Pancreatic Cancer: Molecular and Clinical Advances. Oxford: Blackwell, pp 181193, 1996.
174.
BouvetM, BoldRJ, LeeJ, EvansDB, AbbruzzeseJL, ChiaoPJ, McConkeyDJ, ChandraJ, ChandraS, FangB, RothJA. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer. Ann Surg Oncol15: 681687, 1998.
175.
KirnD, HermistonT, McCormickF. ONYX-015: Clinical data are encouragingNat Med4: 13411342, 1998.
176.
BorstP. Multiple drug resistance: A solvable problem? In: NeoptolemosJP, LemoineNR, Eds. Pancreatic Cancer: Molecular and Clinical Advances. Oxford: Blackwell, pp 157162, 1996.
177.
PedersonLC, BuchsbaumDJ, VickersSM, KanchariaSR, MayoMS, CurielDT, StackhouseMA. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res57: 43254332, 1997.
JinX, NguyenD, ZhangWW, KuritsisAP, RothJA. Cell cycle arrest and inhibition of tumor cell proliferation by p 16INK4 mediated by an adenovirus vector. Cancer Res55: 32503253, 1995.
180.
SchmidRM, WeidenbachH, YamagushiH, LuhrssH, LiptayS, AdlerG. Direct gene transfer into rat pancreas using DNA liposomes. Eur J Clin Invest28: 220225, 1998.
181.
Vander HeidenMG, ThompsonCB. Bcl-2 proteins: Regulators of apoptosis or mitochondrial homeostasis?Nat Cell Biol1: E209E216, 1999.
182.
WebbA, CunninghamD, CotterF, ClarkePA, diStefanoF, RossP, CorboM, DziewanowskaZ. BCL-2 antisense therapy in patients with non-Hodgkin's lymphoma. Lancet349: 11371141, 1997.
183.
MoniaBP, HolmlundJ, DorrFA. Antisense approaches for the treatment of cancer. Cancer Invest18: 635650, 2000.
184.
FreytagSO, RogulskiKR, PaierlliDL, GilbertJD, KimJH. A novel theree-pronged approach to kill cancer cells selectively: Concomitant viral, double suicide gene and radiotherapy. Human Gene Ther9: 13231333, 1998.
185.
DematteoRP, McClaneSJ, FisherK, YehH, ChuG, BurkeC, RaperSE. Engineering tissue-specific expression of a recombinant adenovirus-selective transgene transcription in the pancreas using the amylase promotor. J Surg Res72: 15551561, 1997.
186.
JaffeeEM. A phase I clinical trial of lethally irradiated allogenic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenocarcinoma. Human Gene Ther9: 19511971, 1998.
187.
BullfinchT. The Golden Fleece-Medea. In: Bullfinch's Mythology. New York: Avenel Books, pp 129134, 1978.
188.
KaufmannSH, EarnshawWC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res256: 4249, 2000.
189.
KroemerG, ReedJC. Mitochondrial control of cell death. Nat Med6: 513519, 2000.
190.
KlementG, BaruchelS, RakJ, ManS, ClarkK, HicklinDJ, BohlenP, KerbelRS. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Cancer Invest105: R15R24, 2000.
